Biohaven's rimegepant for preventive treatment of migraine published in the lancet

New haven, conn., dec. 16, 2020 /prnewswire/ --- biohaven pharmaceutical holding company ltd. (nyse: bhvn) announced today that the lancet published the company's positive results from a phase 3 clinical trial of rimegepant for the preventive treatment of migraine in adults. these data...
BHVN Ratings Summary
BHVN Quant Ranking